Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
37,934people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
Alirocumab
Evolocumab
No clear effect on major heart events−16%
randomisedThe trial randomly assignedassigned by chance
PCSK9 inhibitors
control (placebo or standard care)
Lowered LDL cholesterol−52.7
Lowered major heart events−21%
randomisedthe abstract, start to end
… not statistically significant (OR: 0.84; 95% CI: 0.68-1.03).
… reduced LDL-C (mean difference [MD]: - 52.7 mg/dL; 95% CI: - 61.2 to - 44.1) and lowered the risk of MACE (odds ratio [OR]: 0.79; 95% CI: 0.68-0.93).
← favours treatmentfavours comparator →
could be chanceMACEAlirocumab vs Evolocumab
OR 0.840.68–1.03
LDL-CPCSK9 inhibitors vs control (placebo or standard care)
−52.7−61.2 to −44.1
MACEPCSK9 inhibitors vs control (placebo or standard care)
OR 0.790.68–0.93
PCSK9 inhibitorsLipidsCardiovascular events
PCSK9 inhibitors × lipidshelps?settled
unlikelylikely
0.93not counted
PCSK9 inhibitors × cardiovascular eventshelps?settled
unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
1 / 7